drugset / Trial / NCT06737081

SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

NCT06737081

Phase 2 Recruiting 60 enrolled Shenzhen Salubris Pharmaceuticals Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of SAL-0951 in the treatment of chemotherapy-induced anemia (CIA) in patients with non-myeloid malignancies

Timeline

Start
2024-09-14
Primary completion
2025-12-31
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Enarodustat Small molecule 4 mg
Subject Enarodustat Small molecule 5 mg

Indications